



HUTCHISON CHINA MEDITECH LIMITED

2015 Annual Report and Notice of Annual General Meeting

London: Tuesday, March 15, 2016: Hutchison China MediTech Limited (“Chi-Med”) (AIM:HCM) today announces that its 2015 Annual Report together with the Notice of Annual General Meeting and the Form of Proxy have been posted to shareholders. The documents can be accessed from the website of Chi-Med (www.chi-med.com).

Ends

Enquiries

Chi-Med

Christian Hogg, CEO

Telephone: +852 2121 8200

Panmure Gordon (UK) Limited

Richard Gray
Andrew Potts

Telephone: +44 20 7886 2500

Citigate Dewe Rogerson

Anthony Carlisle
David Dible

Telephone: +44 20 7638 9571

Mobile: +44 7973 611 888

Mobile: +44 7967 566 919

Notes to Editors

About Chi-Med

Chi-Med is a China-based, globally-focused healthcare group which researches, develops, manufactures and sells pharmaceuticals and health-related consumer products. Its Innovation Platform focuses on discovering and developing innovative therapeutics in oncology and autoimmune diseases for the global market. Its Commercial Platform manufactures, markets and distributes prescription drugs and consumer health products in China.

Chi-Med is majority owned by the multinational conglomerate CK Hutchison Holdings Limited (SEHK: 0001). For more information, please visit: www.chi-med.com.